Zynex, Inc., through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography triggered electrical stimulation device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; and E-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, and knee braces for knee support. Further, it offers Zynex Fluid Monitoring System (CM-1500), a fluid volume monitor, which is a non-invasive medical device for monitoring relative fluid volume changes used in operating and recovery rooms to detect fluid loss during surgery and internal bleeding during recovery; Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser-based noninvasive co-oximeter; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; hemodynamic monitoring; and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.
Employees - 1000,
CEO - Thomas Sandgaard,
Sector - Healthcare,
Country - US,
Market Cap -
Altman ZScore(max is 10): 2.6, Piotroski Score(max is 10): 4, Working Capital: $40097000, Total Assets: $105759000, Retained Earnings: $19378000, EBIT: -7632000, Total Liabilities: $84985000, Revenue: $172401000
- Current Price $ - Analyst Target Price $Ticker | ZYXI |
Index | |
Curent Price | |
Change | |
Market Cap | |
Average Volume | |
Income | |
Sales | |
Book Value/Share | |
Cash/Share | |
Dividend Est | |
Dividend TTM | |
Dividend Ex-Date | |
Employees | |
Moving Avg 20days | |
Moving Avg 50days | |
Moving Avg 200days | |
Shares Outstanding | |
Earnings Date | |
Inst. Ownership |
Price/Earnings | |
Forwad P/E | |
PE Growth | |
Price/Sales | |
Price/Book | |
Price/Cash | |
Price/FCF | |
Quick Ratio | |
Current Ratio | |
Debt/Equity | |
Return on Assets | |
Return on Equity | |
Return on Investment | |
Gross Margin | |
Ops Margin | |
Profit Margin | |
RSI | |
BETA(β) | |
From 52week Low | |
From 52week High |
EPS | |
EPS next Year | |
EPS next Qtr | |
EPS this Year | |
EPS next 5 Year | |
EPS past 5 Year | |
Sales past 5 Year | |
EPS Y/Y | |
Sales Y/Y | |
EPS Q/Q | |
Sales Q/Q | |
Sales Surprise | |
EPS Surprise | |
ATR(14) | |
Perf Week | |
Perf Month | |
Perf Quarter | |
Perf Year | |
Perf YTD | |
Target Price |
AryaFin Engine© - An AI FinTech Venture - 2024-25 Disclaimer